Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Conditions
Keywords
Open Label, Dietary Supplements, Alzheimer's Disease, Mild Cognitive Impairment (MCI), Intervention, early phase clinical trial, blood based biomarkers
Brief summary
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology
Interventions
COMBINATION_PRODUCTnatural product combination-1 (NPC1)
parthenolide plus ipriflavone
Sponsors
Massachusetts General Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Analytical chemists running the biomarker analyses are blind to whether participants are in the lead in or active phase of the intervention
Intervention model description
Single arm, lead-in with blood-based biomarkers collected before and after treatment with a natural product combination (NPC1)
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 55 and older, male and female; 2. Subjective Cognitive Impairment or MCI or AD dementia per NIA-AA 2011 criteria; 3. Clinical Dementia Rating \< or = to 2 and Mini Mental Status Exam \> or = to 16; 4. Modified Hachinski Ischemic Score \< or = to 4 5. Geriatric Depression Scale - 15 \< 6 documenting absence from significant depressive syndromes 6. Other medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable \> or = to 3-months ; 7. Biomarker evidence of AD pathology: Plasma abeta42/40 ratio \< or = to 0.12 AND Plasma p-tau217 \> or = to 0.25 OR Amyloid PET positive (centiloid \> or = to 20) as part of routine clinical care. 8. Sufficient vision and hearing to complete all tests 9. Study partner available with frequent (at least 1 hour/day or 1 day/week) contact with participant to provide collateral information about cognition, daily functioning, adverse events reporting, and support for study drug intake 10. General health status that will not interfere with the ability to complete the prospective study (these conditions are listed below in the study exclusion list)
Exclusion criteria
1. CDR \> 2 MMSE \< 16; 2. Significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke); 3. Alcohol or substance abuse according to DSM-IV criteria within the last 2 years 4. Major depressive disorder or anxiety within the last year; Schizophrenia, bipolar disorder or other major psychiatric disorder defined by DSM-IV criteria 5. Abnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable) 6. Unstable or significantly symptomatic CVD (e.g. CAD with frequent angina, CHF with dyspnea at rest) 7. Hypertension: defined as uncontrolled BP \> 160/100 8. Clinical symptomatic orthostatic hypotension 9. Diabetes mellitus that requires insulin injections 10. Hachinski ischemic score \> or = to 4 11. Cancer within the last 5 years, apart from localized prostate cancer (Gleason Grade \< 3) and non-metastatic skin cancers (melanoma). 12. Illness that requires \>1 visit /month to a clinician 13. Medications and dietary supplements: * a. AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemab * b. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to enrollment is permitted) * c. CNS active meds that have not been on stable doses for at least 2 months e.g., cimetidine, beta-blockers, and SSRIs * d. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounted for a period of five half-lives prior to baseline visit * e. Over the counter supplements are not by themselves exclusionary, however, participants are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these product are recorded 14. Participation in any Alzheimer's Disease interventional trial. Participation in other non-AD related trials will be evaluated at the discretion of the investigator 15. Currently pregnant. Positive pregnancy tests during the course of the trial will be evaluated at the discretion of the investigator. Women of Child Bearing Potential (WOCBP) For the purposes of this study, women of childbearing potential are defined as all women who are capable of becoming pregnant, unless they meet one of the following criteria: 1. 12-months post-menopausal 2. Post-hysterectomy/surgically sterile If a female Participant does not meet either of these criteria they will be considered of childbearing potential and will have a serum pregnancy test performed at Screening, Visit 3 (2 months), Visit 6 (5 months), and Visit 10 (8 months).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| plasma p-tau217 | 6 months | Intra-individual changes from pre-treatment observational period to post-treatment interventional period |
| plasma glial fibrillary acidic protein | 6 months | Intraindividual changes |
| plasma neurofilament light chain | 6 months | Intra-individual changes |
| plasma abeta42 / abeta40 | 6 months | Intraindividual changes |
| Safety and Tolerability of NPC1 | Baseline through 6 months | Assessment of Adverse Events Related to NPC1 Treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| plasma hsTNFalpha | 6 months | intra-individual changes |
Countries
United States
Contacts
CONTACTGene Bowman, N.D., M.P.H.
CONTACTBrianna Wang
PRINCIPAL_INVESTIGATORGene Bowman, ND, MPH
Harvard/Massachusetts General Hospital
Outcome results
None listed